FDA Says Remdesivir Used With Hydroxychloroquine May Reduce Its Effectiveness

Save

6/15/2020Updated: 6/15/2020

The Food and Drug Administration (FDA) warned on Monday that co-administering antiviral drug remdesivir with chloroquine phosphate or hydroxychloroquine sulfate may reduce its anti-viral activity.

In an alert (pdf) on Monday, the FDA said chloroquine phosphate (CQ) and hydroxychloroquine sulfate (HCQ) is “unlikely to be effective in treating COVID-19” and that it’s potential benefits don’t outweigh the potential risks, which is a requirement for Emergency Use Authorization (EUA).

China’s Footprint Is Clear in Kashmir Crisis, Analysts Say

Taiwan’s Tougher China Stance Should Bolster Support From Other Nations: Experts

On the Brink of a Multipolar World, India’s Grand Strategy Is Largely Defined by China, Analysts Say

CCP–Cook Islands Deal Raises Concerns for New Zealand, US, Australia